REG - Futura Medical PLC - Futura Medical Annual General Meeting Results

Futura MedicalAnnouncement

22/06/2023 15:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230622:nRSV6410Da&default-theme=true

RNS Number : 6410D  Futura Medical PLC  22 June 2023

 

22 June 2023

 Futura Medical plc

("Futura" or the "Company")

Futura Medical Announces Annual General Meeting Results

 

 

Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical
company developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys® drug delivery technology currently focused
on sexual health, today announces that at its Annual General Meeting, held
today at 10:00am BST, the shareholders duly passed all resolutions.

 

The total number of votes received on each resolution were as follows:

 

 

                                                                                                    Voting For                                                    Voting Against
                    Number of votes(i)                                                              %                              Number of votes                %                                Total Votes                      % ISC       Votes withheld(ii)
 Resolution 1       To receive and adopt the annual report of the directors and the financial       69,770,830                     99.98%                         11,289                           0.02%                            69,782,119  24.22%              19,089
                    statements for the financial

                    year ended 31 December 2022 and the report of the appointed auditors thereon.
 Resolution 2       To re-elect John Clarke as a Director of the Company, who retires by rotation   69,751,950                     99.96%                         26,170                           0.04%                            69,778,120  24.22%              23,089
                    in accordance with the

                    Company's articles of association.
 Resolution 3       To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office    69,717,388                     99.91%                         64,733                           0.09%                            69,782,121  24.22%              19,089
                    until the conclusion of

                    the next annual general meeting of the Company.
 Resolution 4       To authorise the Directors to determine the remuneration of Grant Thornton UK   69,720,243                     99.91%                         61,879                           0.09%                            69,782,122  24.22%              19,089
                    LLP as auditor of the

                    Company.
 Resolution 5       To authorise that the Directors of the Company are generally and                69,231,840                     99.87%                         90,153                           0.13%                            69,321,993  24.06%              479,219
                    unconditionally authorised for the purposes of section 551

                    Companies Act 2006 (the "CA 2006") to exercise all the powers of the Company
                    to allot shares in the

                    Company and to grant rights to subscribe for or to convert any security into
                    shares in the Company
 Resolution 6(iii)  A Special Resolution, subject to the passing of Resolution 5 set out above,     69,019,760                     99.59%                         287,234                          0.41%                            69,306,994  24.05%              494,219
                    that authorises the Directors to allot equity

                    securities (as defined in the CA 2006) for cash under the authority given by
                    that resolution and/or to

                    sell ordinary shares held by the Company as treasury shares for cash as if
                    section 561 of the CA 2006

                    did not apply to any such allotment or sale, to be limited to £57,626
 Resolution 7       A Special Resolution, subject to the passing of Resolution 6 set out above,     69,019,007                     99.57%                         298,988                          0.43%                            69,317,995  24.06%              483,219
                    that authorises the Directors, in

                    addition to any authority granted under Resolution 6, to allot equity
                    securities (as defined in the CA

                    2006) for cash under the authority given by that resolution and/or to sell
                    ordinary shares held by the

                    Company as treasury shares for cash as if section 561 of the CA 2006 did not
                    apply to any such

                    allotment or sale, limited to £57,626, with such authority to be used only
                    for the purposes of financing

 

ⁱ Where shareholders appointed the Chairman as their proxy with discretion
as to voting, their votes were cast in favour of the resolution

ⁱⁱ A vote withheld is not a vote in law and is not counted towards the
votes cast "For" or "Against" a resolution

ⁱⁱⁱ Special Resolution (75% majority required)

The total voting rights of the Company as at 10:00 am on 22 June 2023 (the
time by which shareholders wanting to vote at the AGM were required to be
entered on the register) was 288,133,957 ordinary shares of 0.2p each. The
Company does not hold any shares in treasury

 

-ENDS-

For further information, please contact:

 

Futura Medical plc

James Barder, Chief Executive Officer

Angela Hildreth, Finance Director and COO

Email: investor.relations@futuramedical.com

Tel: +44 (0) 1483 685 670

www.futuramedical.com (http://www.futuramedical.com/)

 

Nominated Adviser and Sole Broker:

 

Liberum

Phil Walker/ Richard Lindley/ Ben Cryer

Tel: +44 (0) 20 3100 2000

 

For media enquiries please contact:

 

Optimum Strategic Communications

Hollie Vile/ Jonathan Edwards/ Zoe Bolt

Email: futuramedical@optimumcomms.com

Tel: +44 (0) 203 882 9621

 

About Futura Medical plc

 

Futura Medical plc (AIM: FUM), is a pharmaceutical company developing a
portfolio of innovative products based on its proprietary, transdermal
DermaSys® technology. Each DermaSys® formulation is separately patented and
specifically tailored for the selected indication and application, as well as
being optimised for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and consumer
healthcare markets as appropriate. Development and commercialisation
strategies are designed to maximise product differentiation and value creation
whilst minimising risk.

 

MED3000 is Futura's topical gel formulation that is a novel treatment for
erectile dysfunction (ED) through a unique evaporative mode of action. Futura
has conducted two Phase 3 studies using MED3000 in ED; FM57 study which
enabled Futura to be granted a CE Mark in 2021 and FM71 which enabled Futura
to be granted US marketing authorisation. Both studies demonstrated that
MED3000 presents an effective clinically proven treatment for ED with a rapid
speed of onset and a favourable benefit versus risk profile ideally suited for
an 'Over the Counter' classification.

 

Eroxon® is FDA approved in the US, CE marked in Europe and UKCA marked in
the UK as a clinically proven topical treatment for adult men with
erectile dysfunction under the brand Eroxon® with a key claim of "Helps you
get an erection within 10 minutes". Eroxon® is the agreed brand name in
certain regions such as the EU whereas MED3000 continues to be the internal
code name used by the Company and also in reference to countries where
regulatory approval or commercial distribution agreements have not yet been
achieved. www.eroxon.com (http://www.eroxon.com)

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market
of the London Stock Exchange. www.futuramedical.com
(http://www.futuramedical.com/) .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEMFLEEDSEFM